Drugs / ChimeriVax-WN02
ChimeriVax-WN02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00746798 | Oct 2008 → Jun 2009 | West Nile fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00442169 | Dec 2005 → Jun 2008 | West Nile fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChimeriVax-WN02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00746798 ↗ |
| Known as | ChimeriVax West Nile vaccine | “Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults” NCT00746798 ↗ |
| Known as | ChimeriVax WN02 vaccine | “Participants randomized to receive ChimeriVax WN02 vaccine, low dose” NCT00746798 ↗ |
| Modality | Vaccine | “ChimeriVax-WN02 is a live, attenuated chimeric vaccine for protection against West Nile virus.” PMID 21148499 ↗ Jan 2011 |
| Route | Subcutaneous | “Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.” NCT00442169 ↗ |